In the name of God
Histiocytoses describe a diverse group of proliferative disorders involving dentritic cells and macrophages. They include a spectrum of diseases including a reactive inflammatory accumulation of cells, pathologic immune activation, or neoplastic clonal proliferation.
Revision in the classification of histiocytoses is based on histology, phenotype, molecular alterations, , clinical and imaging characteristics. This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome.
The broad spectrum of clinical symptoms and rarity of histiocytosis disordrers make the diagnosis difficult. The unclear nature, the heterogeneous course of the disease from an asymptomatic form to those with various clinical symptoms, the diverse prognosis and the risk of long-term complications cause these group of disorders to remain a major challenge for medicine.
Advanced molecular technologies are resulting in new breakthroughs in understanding the pathophysiology of histiocytic disorders that are changing the field. One of the recent advances includs BRAF V600Emutation, responsible for activation of the MAPKinase RAS-RAF-MEK-ERK cell signaling pathway in pathologic histiocytes, is present in ~55% of LCH cases and was associated with recurrence and high-risk presentation .Also responses to BRAF inhibitors Vemurafenib, in patients with BRAF V600E-mutated LCH confirms that BRAF V600E is a driver mutation in LCH, that is one of the most important group of histiocytosis disorders.
Duo to many challenges in diagnosis and treatment of Histiocytosis disorders in children the Department of ” Pediatric Hematology -Oncology “decided to held the “11th international Hematlogy-Oncology meeting” as title of “Updates in Histiocytosis “. This meeting will be held by clollaboration of many great and scientific authors of “International Histiocyte Society “ , and great ” internal collegues” .
Meeting will be held in beautiful Kish island of Iran for 2 days ; 23 & 24 of NOV 2018.
It is our pleasure to invite all of our dear collegues for participation and sharing in this meeting and we hope this meeting would be helpful for all of our dear collegues .
Dr Gholamreza Bahoush- Dr Bibi shahin shamsian